Avadel Pharmaceuticals (NASDAQ:AVDL) Raised to “Strong-Buy” at Lifesci Capital

Avadel Pharmaceuticals (NASDAQ:AVDL) was upgraded by Lifesci Capital to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.73 EPS.

AVDL has been the subject of a number of other reports. Wells Fargo & Company started coverage on shares of Avadel Pharmaceuticals in a report on Tuesday. They issued an “equal weight” rating and a $16.00 target price for the company. Zacks Research raised shares of Avadel Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Avadel Pharmaceuticals in a research note on Friday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Avadel Pharmaceuticals in a report on Thursday, May 8th. Finally, UBS Group boosted their target price on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $19.14.

Avadel Pharmaceuticals Price Performance

NASDAQ:AVDL opened at $14.99 on Wednesday. The firm has a market cap of $1.46 billion, a PE ratio of -499.67 and a beta of 1.58. The company has a 50-day moving average of $11.87 and a 200 day moving average of $9.69. Avadel Pharmaceuticals has a 1-year low of $6.38 and a 1-year high of $16.66.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. The firm had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The company’s quarterly revenue was up 64.1% on a year-over-year basis. During the same period last year, the firm earned ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Avadel Pharmaceuticals will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Avadel Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its holdings in Avadel Pharmaceuticals by 164.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $29,000 after buying an additional 2,055 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Avadel Pharmaceuticals in the 2nd quarter valued at $65,000. Tower Research Capital LLC TRC increased its stake in shares of Avadel Pharmaceuticals by 217.5% in the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock worth $78,000 after acquiring an additional 6,025 shares during the period. Exencial Wealth Advisors LLC purchased a new position in shares of Avadel Pharmaceuticals during the first quarter worth $82,000. Finally, Thoroughbred Financial Services LLC acquired a new position in Avadel Pharmaceuticals during the first quarter valued at $82,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.